Innovating Works

LUDGER

Desconocido
NanoCarb: Glyco Nanoparticles for Applications in Advance Nanomedicine LUDGER LIMITED participó en un H2020: H2020-MSCA-ITN-2018 The advance of nanomedicine requires the development of novel materials with tailored properties, controlled circulation, optimal targeting...
2018-08-20 - 2023-03-31 | Financiado
A4B: Analytics for Biologics LUDGER LIMITED participó en un H2020: H2020-MSCA-ITN-2017 Qualitative and quantitative analysis and purification of therapeutic protein species (TP-S) – coded by the same gene, thus chemically often...
2017-08-29 - 2022-03-31 | Financiado
GlySign: Exploitation of Glycosylation Signatures for Precision Medicine LUDGER LIMITED participó en un H2020: H2020-MSCA-ITN-2016 GlySign is a research training network for the translation of glycomic clinical biomarkers for Precision Medicine (PM). Complex, distinctive...
2016-07-06 - 2020-09-30 | Financiado
GlyCoCan: Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therap... LUDGER LIMITED participó en un H2020: H2020-MSCA-ITN-2015 Colorectal cancer (CRC) is a major worldwide cancer burden with about 1.4 million cases in 2012 and an annual mortality of approximately 700...
2015-08-07 - 2019-08-31 | Financiado
EUROGLYCOARRAYS: Development of carbohydrate array technology to systematically explore the functional role of glycan... LUDGER LIMITED participó en un FP7: The development and production of glycoarrays will provide the foreground knowledge necessary to lead to a step change in the diagnosis and...
Financiado
HIGHGLYCAN: Methods for high throughput HTP analysis of protein glycosylation LUDGER LIMITED participó en un FP7: Glycosylation is a post-translational modification that enriches protein complexity and function. Dysregulation of glycosylation is associat...
Financiado
IBD-BIOM: Diagnostic and prognostic biomarkers for inflammatory bowel diseaseIBD BIOM LUDGER LIMITED participó en un FP7: Inflammatory bowel diseases affect 0.8% of the Europeans, and are associated with high morbidity, definite mortality and an increasing econo...
Financiado
GLYCOPAR: Parasite glycobiology and anti parasitic strategies LUDGER LIMITED participó en un FP7: "Protozoan parasites and helminths are the cause of some of the most devastating diseases worldwide and a major effort is needed to be able...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.